|
Astrazeneca Plc (NASDAQ: AZN) |
|
Price: $159.5500
$-0.09 
-0.056%
|
| Day's High:
| $161.49949645996094
| Week Perf:
| -1.94 %
|
| Day's Low: |
$ 159.28 |
30 Day Perf: |
0.66 % |
| Volume (M): |
653,934 |
52 Wk High: |
$ 210.52 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$179.19 |
| Open: |
$161.43 |
52 Wk Low: |
$144.30 |
|
|
| Market Capitalization (Millions $) |
124,609 |
| Shares
Outstanding (Millions) |
781 |
| Employees |
83,100 |
| Revenues (TTM) (Millions $) |
73,196 |
| Net Income (TTM) (Millions $) |
12,681 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
2,810 |
Business Description
AstraZeneca Plc is a global pharmaceutical and biopharmaceutical company, headquartered in Cambridge, England, with research and development centers in Sweden, the United States and China. It is one of the largest pharmaceutical companies in the world and operates in over 100 countries.
The company was formed in 1999 through the merger of two established pharmaceutical companies, Astra AB of Sweden and Zeneca Group plc of the UK. AstraZeneca specializes in the development and marketing of prescription drugs for a variety of medical conditions, including cardiovascular, respiratory, and oncology diseases, among others.
AstraZeneca has a strong commitment to innovation, with a significant portion of its revenue reinvested into research and development. It operates several research and development centers worldwide, focusing on therapeutic areas that include oncology, respiratory, and cardiovascular disease. The company's research and development efforts have led to the development of a wide range of life-saving drugs, such as Seloken, Atacand, Crestor, Symbicort, and Imfinzi.
AstraZeneca is also committed to sustainability and to providing a positive impact on the environment and society. The company operates with a strong emphasis on environmental responsibility and sustainability, working towards the reduction of greenhouse gas emissions, water conservation, and responsible waste management. The company is also committed to providing access to affordable medicines to underserved populations.
In 2020, AstraZeneca became a household name due to its success in developing a vaccine for COVID-19 in collaboration with the University of Oxford. The vaccine, which requires two doses, has been authorized in many countries around the world and is playing a crucial role in the global fight against the pandemic.
AstraZeneca is publicly traded on the London Stock Exchange and is a constituent of the FTSE 100 index. It is currently led by CEO Pascal Soriot. As of 2021, the company had approximately 76,100 employees worldwide and reported revenue of $26.6 billion.
Company Address: 1 Francis Crick Avenue Cambridge 0
Company Phone Number: 3749 5000 Stock Exchange / Ticker: NASDAQ AZN
|
|
| |
| US |
|
 40.81 % |
of total Revenue |
| Emerging Markets |
|
25.63 % |
of total Revenue |
| Europe |
|
20.47 % |
of total Revenue |
| Rest of World |
|
8.6 % |
of total Revenue |
| Total Oncology |
|
40.34 % |
of total Revenue |
| Total Oncology US |
|
19.05 % |
of total Revenue |
| Total Oncology Emerging Markets |
|
9.11 % |
of total Revenue |
| Total Oncology Europe |
|
8.31 % |
of total Revenue |
| Total Oncology Rest of World |
|
3.88 % |
of total Revenue |
| Tagrisso |
|
12.35 % |
of total Revenue |
| Tagrisso US |
|
5.22 % |
of total Revenue |
| Tagrisso Emerging Markets |
|
3.36 % |
of total Revenue |
| Tagrisso Europe |
|
2.42 % |
of total Revenue |
| Tagrisso Rest of World |
|
1.36 % |
of total Revenue |
| Imfinzi |
|
10.32 % |
of total Revenue |
| Imfinzi US |
|
5.97 % |
of total Revenue |
| Imfinzi Emerging Markets |
|
1.09 % |
of total Revenue |
| Imfinzi Europe |
|
2.11 % |
of total Revenue |
| Imfinzi Rest of World |
|
1.15 % |
of total Revenue |
| Calquence |
|
5.99 % |
of total Revenue |
| Calquence US |
|
3.98 % |
of total Revenue |
| Calquence Emerging Markets |
|
0.4 % |
of total Revenue |
| Calquence Europe |
|
1.33 % |
of total Revenue |
| Calquence Rest of World |
|
0.28 % |
of total Revenue |
| Lynparza |
|
5.58 % |
of total Revenue |
| Lynparza US |
|
2.44 % |
of total Revenue |
| Lynparza Emerging Markets |
|
1.14 % |
of total Revenue |
| Lynparza Europe |
|
1.56 % |
of total Revenue |
| Lynparza Rest of World |
|
0.45 % |
of total Revenue |
| Enhertu |
|
3.06 % |
of total Revenue |
| Enhertu Emerging Markets |
|
1.14 % |
of total Revenue |
| Enhertu Europe |
|
0.35 % |
of total Revenue |
| Enhertu Rest of World |
|
0.17 % |
of total Revenue |
| Zoladex |
|
1.88 % |
of total Revenue |
| Zoladex US |
|
0.03 % |
of total Revenue |
| Zoladex Emerging Markets |
|
1.43 % |
of total Revenue |
| Zoladex Europe |
|
0.27 % |
of total Revenue |
| Zoladex Rest of World |
|
0.15 % |
of total Revenue |
| Truqap |
|
1.24 % |
of total Revenue |
| Truqap US |
|
1 % |
of total Revenue |
| Truqap Emerging Markets |
|
0.04 % |
of total Revenue |
| Truqap Europe |
|
0.14 % |
of total Revenue |
| Truqap Rest of World |
|
0.06 % |
of total Revenue |
| Imjudo |
|
0.59 % |
of total Revenue |
| Imjudo US |
|
0.39 % |
of total Revenue |
| Imjudo Emerging Markets |
|
0.04 % |
of total Revenue |
| Imjudo Europe |
|
0.09 % |
of total Revenue |
| Imjudo Rest of World |
|
0.08 % |
of total Revenue |
| Datroway |
|
0.13 % |
of total Revenue |
| Datroway Emerging Markets |
|
0 % |
of total Revenue |
| Oncology Others |
|
0.72 % |
of total Revenue |
| Oncology Others US |
|
0.02 % |
of total Revenue |
| Oncology Others Emerging Markets |
|
0.48 % |
of total Revenue |
| Oncology Others Europe |
|
0.03 % |
of total Revenue |
| Oncology Others Rest of World |
|
0.2 % |
of total Revenue |
| CVRM |
|
21.73 % |
of total Revenue |
| CVRM US |
|
4.63 % |
of total Revenue |
| CVRM Emerging Markets |
|
10.03 % |
of total Revenue |
| CVRM Europe |
|
5.78 % |
of total Revenue |
| CVRM Rest of World |
|
1.28 % |
of total Revenue |
| Farxiga |
|
14.3 % |
of total Revenue |
| Farxiga US |
|
2.95 % |
of total Revenue |
| Farxiga Emerging Markets |
|
5.66 % |
of total Revenue |
| Farxiga Europe |
|
5.01 % |
of total Revenue |
| Farxiga Rest of World |
|
0.69 % |
of total Revenue |
| Crestor |
|
2.07 % |
of total Revenue |
| Crestor US |
|
0.08 % |
of total Revenue |
| Crestor Emerging Markets |
|
1.77 % |
of total Revenue |
| Crestor Europe |
|
0 % |
of total Revenue |
| Crestor Rest of World |
|
0.22 % |
of total Revenue |
| Brilinta |
|
1.4 % |
of total Revenue |
| Brilinta US |
|
0.67 % |
of total Revenue |
| Brilinta Emerging Markets |
|
0.46 % |
of total Revenue |
| Brilinta Europe |
|
0.25 % |
of total Revenue |
| Brilinta Rest of World |
|
0.02 % |
of total Revenue |
| Lokelma |
|
1.19 % |
of total Revenue |
| Lokelma US |
|
0.51 % |
of total Revenue |
| Lokelma Emerging Markets |
|
0.22 % |
of total Revenue |
| Lokelma Europe |
|
0.22 % |
of total Revenue |
| Lokelma Rest of World |
|
0.24 % |
of total Revenue |
| Seloken |
|
1.03 % |
of total Revenue |
| Seloken Emerging Markets |
|
1 % |
of total Revenue |
| Seloken Europe |
|
0.03 % |
of total Revenue |
| Seloken Rest of World |
|
0.01 % |
of total Revenue |
| Roxadustat |
|
0.47 % |
of total Revenue |
| Roxadustat Emerging Markets |
|
0.47 % |
of total Revenue |
| Wainua |
|
0.36 % |
of total Revenue |
| Wainua US |
|
0.35 % |
of total Revenue |
| Wainua Emerging Markets |
|
0.01 % |
of total Revenue |
| Wainua Europe |
|
0.01 % |
of total Revenue |
| CVRM Others |
|
0.91 % |
of total Revenue |
| CVRM Others US |
|
0.08 % |
of total Revenue |
| CVRM Others Emerging Markets |
|
0.45 % |
of total Revenue |
| CVRM Others Europe |
|
0.27 % |
of total Revenue |
| CVRM Others Rest of World |
|
0.11 % |
of total Revenue |
| Total Respiratory Immunology |
|
13.9 % |
of total Revenue |
| Total Respiratory Immunology US |
|
6.54 % |
of total Revenue |
| Total Respiratory Immunology Emerging Markets |
|
3.1 % |
of total Revenue |
| Total Respiratory Immunology Europe |
|
2.9 % |
of total Revenue |
| Total Respiratory Immunology Rest of World |
|
1.37 % |
of total Revenue |
| Symbicort |
|
4.91 % |
of total Revenue |
| Symbicort US |
|
2.03 % |
of total Revenue |
| Symbicort Emerging Markets |
|
1.36 % |
of total Revenue |
| Symbicort Europe |
|
0.95 % |
of total Revenue |
| Symbicort Rest of World |
|
0.56 % |
of total Revenue |
| Fasenra |
|
3.37 % |
of total Revenue |
| Fasenra US |
|
2.03 % |
of total Revenue |
| Fasenra Emerging Markets |
|
0.2 % |
of total Revenue |
| Fasenra Europe |
|
0.82 % |
of total Revenue |
| Fasenra Rest of World |
|
0.32 % |
of total Revenue |
| Breztri |
|
2.04 % |
of total Revenue |
| Breztri US |
|
1.05 % |
of total Revenue |
| Breztri Emerging Markets |
|
0.51 % |
of total Revenue |
| Breztri Europe |
|
0.33 % |
of total Revenue |
| Breztri Rest of World |
|
0.16 % |
of total Revenue |
| Tezspire |
|
1.15 % |
of total Revenue |
| Tezspire Emerging Markets |
|
0.07 % |
of total Revenue |
| Tezspire Europe |
|
0.51 % |
of total Revenue |
| Tezspire Rest of World |
|
0.21 % |
of total Revenue |
| Saphnelo |
|
1.17 % |
of total Revenue |
| Saphnelo US |
|
1.01 % |
of total Revenue |
| Saphnelo Emerging Markets |
|
0.03 % |
of total Revenue |
| Saphnelo Europe |
|
0.08 % |
of total Revenue |
| Saphnelo Rest of World |
|
0.04 % |
of total Revenue |
| Pulmicort |
|
0.88 % |
of total Revenue |
| Pulmicort US |
|
0.01 % |
of total Revenue |
| Pulmicort Emerging Markets |
|
0.7 % |
of total Revenue |
| Pulmicort Europe |
|
0.11 % |
of total Revenue |
| Pulmicort Rest of World |
|
0.06 % |
of total Revenue |
| Airsupra |
|
0.28 % |
of total Revenue |
| Airsupra US |
|
0.28 % |
of total Revenue |
| Airsupra Emerging Markets |
|
0.01 % |
of total Revenue |
| Respiratory and immunology Others |
|
0.47 % |
of total Revenue |
| Respiratory and immunology Others US |
|
0.13 % |
of total Revenue |
| Respiratory and immunology Others Emerging Markets |
|
0.23 % |
of total Revenue |
| Respiratory and immunology Others Europe |
|
0.1 % |
of total Revenue |
| Respiratory and immunology Others Rest of World |
|
0.01 % |
of total Revenue |
| Vaccines Immune Therapies |
|
1.44 % |
of total Revenue |
| Vaccines Immune Therapies US |
|
0.36 % |
of total Revenue |
| Vaccines Immune Therapies Emerging Markets |
|
0.37 % |
of total Revenue |
| Vaccines Immune Therapies Europe |
|
0.6 % |
of total Revenue |
| Vaccines Immune Therapies Rest of World |
|
0.11 % |
of total Revenue |
| Beyfortus |
|
0.72 % |
of total Revenue |
| Beyfortus US |
|
0.31 % |
of total Revenue |
| Beyfortus Europe |
|
0.16 % |
of total Revenue |
| Beyfortus Rest of World |
|
0.01 % |
of total Revenue |
| Synagis |
|
0.5 % |
of total Revenue |
| Synagis US |
|
-0.01 % |
of total Revenue |
| Synagis Emerging Markets |
|
0.36 % |
of total Revenue |
| Synagis Europe |
|
0.09 % |
of total Revenue |
| Synagis Rest of World |
|
0.05 % |
of total Revenue |
| FluMist |
|
0.46 % |
of total Revenue |
| FluMist US |
|
0.05 % |
of total Revenue |
| FluMist Emerging Markets |
|
0.01 % |
of total Revenue |
| FluMist Europe |
|
0.36 % |
of total Revenue |
| FluMist Rest of World |
|
0.05 % |
of total Revenue |
| Vaccines Immune Therapies Others |
|
0 % |
of total Revenue |
| Vaccines Immune Therapies Others Emerging Markets |
|
0 % |
of total Revenue |
| Total Rare Disease |
|
15.54 % |
of total Revenue |
| Total Rare Disease US |
|
9.23 % |
of total Revenue |
| Total Rare Disease Emerging Markets |
|
1.77 % |
of total Revenue |
| Total Rare Disease Europe |
|
2.73 % |
of total Revenue |
| Total Rare Disease Rest of World |
|
1.81 % |
of total Revenue |
| Ultomiris |
|
8.03 % |
of total Revenue |
| Ultomiris US |
|
4.54 % |
of total Revenue |
| Ultomiris Emerging Markets |
|
0.44 % |
of total Revenue |
| Ultomiris Europe |
|
1.79 % |
of total Revenue |
| Ultomiris Rest of World |
|
1.25 % |
of total Revenue |
| Soliris |
|
3.13 % |
of total Revenue |
| Soliris US |
|
1.86 % |
of total Revenue |
| Soliris Emerging Markets |
|
0.69 % |
of total Revenue |
| Soliris Europe |
|
0.34 % |
of total Revenue |
| Soliris Rest of World |
|
0.24 % |
of total Revenue |
| Strensiq |
|
2.86 % |
of total Revenue |
| Strensiq US |
|
2.27 % |
of total Revenue |
| Strensiq Emerging Markets |
|
0.18 % |
of total Revenue |
| Strensiq Europe |
|
0.21 % |
of total Revenue |
| Strensiq Rest of World |
|
0.2 % |
of total Revenue |
| Koselugo |
|
1.13 % |
of total Revenue |
| Koselugo US |
|
0.37 % |
of total Revenue |
| Koselugo Emerging Markets |
|
0.39 % |
of total Revenue |
| Koselugo Europe |
|
0.27 % |
of total Revenue |
| Koselugo Rest of World |
|
0.09 % |
of total Revenue |
| Rare Disease Others |
|
0.39 % |
of total Revenue |
| Rare Disease Others US |
|
0.19 % |
of total Revenue |
| Rare Disease Others Emerging Markets |
|
0.07 % |
of total Revenue |
| Rare Disease Others Europe |
|
0.11 % |
of total Revenue |
| Rare Disease Others Rest of World |
|
0.02 % |
of total Revenue |
| Total Other medicines |
|
1.65 % |
of total Revenue |
| Total Other medicines US |
|
0.11 % |
of total Revenue |
| Total Other medicines Emerging Markets |
|
1.25 % |
of total Revenue |
| Total Other medicines Europe |
|
0.14 % |
of total Revenue |
| Total Other medicines Rest of World |
|
0.16 % |
of total Revenue |
| Nexium |
|
1.39 % |
of total Revenue |
| Nexium US |
|
0.11 % |
of total Revenue |
| Nexium Emerging Markets |
|
1.04 % |
of total Revenue |
| Nexium Europe |
|
0.09 % |
of total Revenue |
| Nexium Rest of World |
|
0.15 % |
of total Revenue |
| Other Others |
|
0.27 % |
of total Revenue |
| Other Others US |
|
-0.01 % |
of total Revenue |
| Other Others Emerging Markets |
|
0.21 % |
of total Revenue |
| Other Others Europe |
|
0.06 % |
of total Revenue |
| Other Others Rest of World |
|
0.01 % |
of total Revenue |
| Other royalty income |
|
0.16 % |
of total Revenue |
| Other Alliance Revenue |
|
0.01 % |
of total Revenue |
| Farxiga sales milestones |
|
0.15 % |
of total Revenue |
| Other Collaboration Revenue |
|
0.02 % |
of total Revenue |
| UNITED KINGDOM |
|
1.89 % |
of total Revenue |
| Outside the UK |
|
92.58 % |
of total Revenue |
| Rest of Europe |
|
21.13 % |
of total Revenue |
| FRANCE |
|
2.4 % |
of total Revenue |
| GERMANY |
|
4.92 % |
of total Revenue |
| ITALY |
|
1.84 % |
of total Revenue |
| SPAIN |
|
1.93 % |
of total Revenue |
| SWEDEN |
|
4.47 % |
of total Revenue |
| Others Europe |
|
7.35 % |
of total Revenue |
| The Americas |
|
46.43 % |
of total Revenue |
| CANADA |
|
1.62 % |
of total Revenue |
| Other Americas excluding US and Canada |
|
4.48 % |
of total Revenue |
| Asia Africa And Australasia |
|
25.16 % |
of total Revenue |
| AUSTRALIA |
|
0.77 % |
of total Revenue |
| CHINA |
|
11.3 % |
of total Revenue |
| JAPAN |
|
6.05 % |
of total Revenue |
| Other Asia Africa and Australasia excluding Australia China and Japan |
|
4.63 % |
of total Revenue |
| Customer one |
|
13.99 % |
of total Revenue |
| Customer two |
|
10.14 % |
of total Revenue |
